Comprehensive Hereditary Cancer Panel
Use
This test is intended for individuals with a clinical or suspected diagnosis of hereditary cancer syndromes, particularly those who have been diagnosed with early-onset cancer before age 50, have multiple affected family members, a strong family history of cancer, or are of Ashkenazi Jewish descent with a personal or family history of relevant cancers. It analyzes 117 genes associated with hereditary cancer syndromes to aid in the diagnosis and management of patients and their families.
Special Instructions
This test includes the STAT testing option which expedites the delivery of results. Orders must be placed through a qualified healthcare provider, either online or via the test requisition form. Pricing details and additional options such as family testing are available upon request. The panel uses the PGselect Platform and involves sophisticated genetic analysis techniques.
Limitations
The Comprehensive Hereditary Cancer Panel is limited to detecting variants within the 117 genes analyzed. Certain structural variants or rare indels may not be detected. The accuracy of CNV detection may be lower in telomeric and centromeric regions. Known limitations of sequencing and CNV methodologies apply. Test interpretations are dependent on the clinical data provided by the healthcare provider.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided